A randomised comparison of safety and efficacy of triple therapy for 12 weeks, followed by 12 or 36 additional weeks of peginterferon alfa 2b and ribavirin in HCV patients

Trial Profile

A randomised comparison of safety and efficacy of triple therapy for 12 weeks, followed by 12 or 36 additional weeks of peginterferon alfa 2b and ribavirin in HCV patients

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2013

At a glance

  • Drugs Peginterferon alfa-2b/ribavirin (Primary) ; Telaprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Dec 2013 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
    • 29 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top